New Insights on Relexxii's Efficacy
Alora Pharmaceuticals, a notable player in the pharmaceutical industry, has recently announced groundbreaking findings regarding its extended-release formulation of Relexxii. This new research indicates that Relexxii is bioequivalent to the well-known reference product, Concerta, which has been a common treatment option for attention-deficit/hyperactivity disorder (ADHD). The publication, which appears in a respected peer-reviewed journal, underscores the commitment of Alora Pharmaceuticals in enhancing patient access to effective therapeutic solutions.
Study Design and Results
The pivotal pharmacokinetic (PK) studies involved two replicate crossover trials that assessed the pharmacokinetic profiles of Relexxii and Concerta in healthy adults. Conducted in a controlled fasted state, the studies focused on several critical parameters. The results demonstrated that Relexxii aligns closely with the reference product, reflecting similar characteristics in maximum concentration and other relevant metrics over specified timeframes.
Key Findings
These studies confirmed that Relexxii, identified as ODX-methylphenidate ER during the research, exhibited statistical bioequivalence to the OROS-methylphenidate ER tablet known as Concerta. Specifically, the data highlighted consistent performance across various time intervals, such as AUC metrics which are vital for understanding medication efficacy.
Responses from Leadership
The findings have been met with positive feedback from top executives at Alora. Art Deas, the Chief Executive Officer of Alora, expressed his enthusiasm by stating that this breakthrough reinforces the strength of their clinical and development efforts. He emphasized the importance of providing high-quality treatment options for ADHD patients, indicating the company's dedication to improving patient care.
Relexxii’s Design and Availability
Relexxii employs an innovative osmotic pump delivery system, enabling a uniform and controlled release of medication throughout the day. This design feature helps to build trust among healthcare providers and patients, ensuring they feel confident in its therapeutic equivalence to Concerta. The medication is available in several strengths, including 18 mg, 27 mg, 36 mg, 45 mg, 54 mg, 63 mg, and 72 mg, thereby allowing flexibility in dosing which caters to the specific needs of individuals with ADHD.
Growing Clinical Validation
Ahmad Al-Sabbagh, MD., the Vice President of Medical Affairs at Alora Pharmaceuticals and a leader in this significant study, has worked tirelessly to compile a robust body of evidence supporting Relexxii as a reliable option for ADHD treatment. His efforts highlight the growing recognition of Relexxii as a viable alternative for managing ADHD symptoms effectively.
About Alora Pharmaceuticals
Alora Pharmaceuticals, LLC is an umbrella organization that encompasses various specialty pharmaceutical companies. Alora is devoted to advancing innovative treatments while prioritizing quality and accessibility. The company's headquarters is located in Alpharetta, Georgia and it oversees multiple entities within the pharmaceutical sphere, each focused on addressing the needs of patients in unique ways.
Contact Information
For inquiries or more detailed information concerning the ADHD treatment landscape, potential collaborations, or insight into Alora’s contribution to improving medication access, interested parties can reach out to Alora Pharmaceuticals at their headquarters. The address is 1880 McFarland Parkway, Suite 110, Alpharetta, GA 30005, with a direct contact number of 1-678-325-5189.
Frequently Asked Questions
What did the recent studies show about Relexxii?
The recent studies demonstrated that Relexxii is bioequivalent to Concerta, indicating similar pharmacokinetic parameters.
Why is Relexxii an important treatment option?
Relexxii provides an alternative for ADHD management, expanding treatment choices, especially given its unique delivery system.
What are the available strengths of Relexxii?
Relexxii is available in strengths ranging from 18 mg to 72 mg, offering flexibility in treatment.
Who led the pivotal study on Relexxii?
The study was led by Ahmad Al-Sabbagh, MD., the Vice President of Medical Affairs at Alora Pharmaceuticals.
Can Relexxii be considered a safe alternative to Concerta?
Yes, the studies indicated that Relexxii shares a similar safety and tolerability profile compared to Concerta.
